Canadian national consensus guidelines for naloxone prescribing by pharmacists

Tsuyuki, Ross T.; Arora, Vinita; Barnes, Mark; Beazely, Michael A.; Boivin, Michael; Christofides, Anna; Patel, Harsit; Laroche, Julie; Sihota, Aaron; So, Randy

doi:10.1177/1715163520949973

Cited by 14 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the barrier of no-one asking for naloxone has been previously mentioned in other studies evaluating community pharmacy take home naloxone programs [14,[25][26][27][28]. The national consensus guidelines for naloxone prescribing by pharmacists recommends that a naloxone kit be offered to every patient presenting with an opioid prescription [29]. The fact that most pharmacists are waiting for patients to ask for a naloxone kit suggests that continuing education is needed to teach pharmacists how to proactively offer naloxone and initiate conversations with their patients to overcome this barrier.…”

Section: Discussionmentioning

confidence: 99%

Investigating Community Pharmacy Take Home Naloxone Dispensing during COVID-19: The Impact of One Public Health Crisis on Another

2021

Self Cite

View full text Add to dashboard Cite

A recent report found that the number of opioid-related deaths in Ontario in the first 15 weeks of the COVID-19 pandemic was 38.2% higher than in the 15 weeks before the pandemic. Our study sought to determine if pharmacy professionals self-reported an increase or decrease in naloxone provision due to the pandemic and to identify adjustments made by pharmacy professionals to dispense naloxone during the pandemic. A total of 231 Ontario community pharmacy professionals completed an online survey. Pharmacy professionals’ barriers, facilitators, and comfort level with dispensing naloxone before and during the pandemic were identified. The sample consisted of mostly pharmacists (99.1%). Over half (51.1%) reported no change in naloxone dispensing, while 22.9% of respondents reported an increase and 24.7% a decrease. The most common adjustments made during the pandemic were training patients how to administer naloxone over video or phone, delivering naloxone kits, and pharmacy technicians offering naloxone at prescription intake. Over half (55%) of participants said the top barrier for dispensing was that patients did not request naloxone. Naloxone distribution through pharmacies could be further optimized to address the increased incidence of overdose deaths during the pandemic. Future research should investigate the reasons for changes in naloxone dispensing.

show abstract

Section: Discussionmentioning

confidence: 99%

Investigating Community Pharmacy Take Home Naloxone Dispensing during COVID-19: The Impact of One Public Health Crisis on Another

2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our national consensus guidelines for pharmacists, published in 2020, call for naloxone to be offered to all patients receiving an opioid prescription. 11 This recommendation addresses the stigma associated with naloxone by recommending that all patients receiving a prescription opioid should receive a naloxone kit. This means that the burden of the pharmacist needing to identify which patients should have a naloxone kit is removed and the patient no longer needs to feel identified as being "at risk"-all patients with an opioid prescription get a kit!…”

Section: Pharmd Mscmentioning

confidence: 99%

The opioid crisis: Naloxone and pharmacists to the rescue

Beazely¹,

Tsuyuki²

2021

Can Pharm J

Self Cite

View full text Add to dashboard Cite

“…5,6 One way to combat this barrier is through following the national consensus guidelines for pharmacists to offer a naloxone kit to every patient with an opioid prescription. 7 The normalization of dispensing and offering naloxone to all can help to break barriers in pharmacist hesitancy as well as patient stigma. 8…”

Section: Access and Barriersmentioning

confidence: 99%

Frequently asked questions about naloxone: Part 1

et al. 2021

Self Cite

View full text Add to dashboard Cite

Are patients and community members asking complicated questions about naloxone? The goal of this 3-part informational series is to increase pharmacists' knowledge on the frequently asked questions about naloxone, so that they can fill their own knowledge gaps as well as those of their patients. Pharmacists are key to ensuring all those at risk of an opioid overdose, or who are in a position to help, have naloxone and know how to use it. Beyond the signs and symptoms of opioid toxicity, naloxone administration, and the importance of calling 911, pharmacists can also be a resource for emerging research about naloxone and countering myths about it. In this series, we will be addressing real-world questions from pharmacists, service providers and community members about naloxone.

show abstract

Canadian national consensus guidelines for naloxone prescribing by pharmacists

Cited by 14 publications

References 11 publications

Investigating Community Pharmacy Take Home Naloxone Dispensing during COVID-19: The Impact of One Public Health Crisis on Another

Investigating Community Pharmacy Take Home Naloxone Dispensing during COVID-19: The Impact of One Public Health Crisis on Another

The opioid crisis: Naloxone and pharmacists to the rescue

Frequently asked questions about naloxone: Part 1

Contact Info

Product

Resources

About